Related Experiment Video
Updated: Aug 7, 2025

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates
Published on: May 30, 2025
Recurrent Severe Burns Due to Cannabinoid Hyperemesis Syndrome
Eugene Osagie1,2, Omar Mirza1,2
1Psychiatry, Harlem Hospital Center, New York, USA.
Abstract:
Cannabinoid hyperemesis syndrome (CHS) is one of the health outcomes of cannabis use that is showing an increase in the number of reported cases since it first emerged in the medical literature. It is a condition that is now frequently seen by many specialists, including consultation-liaison psychiatrists. CHS is a diagnosis of exclusion that is characterized by the presence of a prolonged history of daily cannabis use, cyclic episodes of nausea and vomiting, and frequent compulsive hot baths. It will be fairly argued that with the surge in the number of marijuana users and frequency of use since the legalization of marijuana in the United States, a proportionate rise in CHS cases is expected over time. In this case report, we present a unique case of a 36-year-old female diagnosed with CHS, and the compensatory behavior of compulsive hot baths led to repeated episodes of severe burns, sepsis, and intensive care unit (ICU) hospitalizations. To the authors' knowledge, this is the first published case of severe burns and sepsis as complications of cannabinoid hyperemesis syndrome.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Burn Injuries
The damage results in the death of skin cells, which can lead to a massive loss of fluid. Dehydration, electrolyte imbalance, and renal and circulatory failure follow, which can be fatal. Burn patients are treated with intravenous fluids to offset...
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Chronic Pancreatitis II: Collaborative Care
Assessment:

